The antinuclear antibody test (ANA) market studied was anticipated to grow with a CAGR of 12.5% during the forecast period. Increasing prevalence of autoimmune disorders, such as Sjogren’s Syndrome, Acute Motor Axonal Neuropathy, and others increased the adoption of ANA testing. According to the Foundation for Peripheral Neuropathy report, in 2019, Guillain-Barre Syndrome(GBS) affected about 3,000-6,000 people each year in the United States. Thus, a rise in the huge target population base is expected to fuel the demand for earlier screening for effective treatment. Also, rising infections due to Epstein–Barr virus, Campylobacter jejuni, and others are likely to drive the global ANA market during the forecast period
Key Market Trends
Immunofluorescence Assay is Expected to Hold the Largest Market Share in the Antinuclear Antibody Test Market
The immunofluorescence (IFA) assay is expected to account for the largest share in the market. Dominance can be attributed to the increased adoption of the technique as the gold standard for ANA testing. Highly sensitive and rapid test results compared to other techniques increased their preference among the clinicians. Furthermore, their ability to identify the various patterns, such as nucleolar, speckled, and homogenous, indicate autoantibodies associated with diseases, fuels the growth of the segment. On the other hand, the ELISA is anticipated to witness the highest CAGR over the forecast period owing to the advancements in the segment. Decreased labor costs to perform the test and operate the systems with highly automated systems reduced the overall cost of analysis. Their higher specificity in the results compared to that of IFA is likely to drive the market during the forecast period.
North America Dominates the Market and it is Expected to do the Same in the Forecast Period
North America is expected to dominate the overall ANA market throughout the forecast period. The dominance is due to several factors such as increasing geriatric population who are more prone to infections due to decreased immunity leading to high demand for earlier diagnosis and effective treatment in the region. For instance, according to the report published by the Centers for Disease Control & Prevention (CDC) in December 2019, people of any age group can develop GBS, but the prevalence of GBS is at increases in the people aged over 65 years which necessitates huge demand due to presence substantial geriatric population in the United States. The presence of key players, such as Alere Inc., Antibodies Inc., Bio-Rad Laboratories, and others in the United States, is expected to fuel the growth of the market in the region, contributing to significant revenue share and propelling the ANA market's revenue in the forecast period.
The ANA market is moderately competitive and consists of several major players. Few of the prominent players currently dominating the market are acquiring the products or other companies to consolidate their market positions across the globe. Launching new products with advanced technologies coupled with recent approvals to diagnose for autoimmune diseases is trending in the market. For example, in June 2018, Grifols received the US Food and Drug Administration (FDA) approval for its novel HELIOS Automated System for IFA used as diagnosis examination for Lupus and ANCA-associated Vasculitis. The automated tests enable labs to standardize and speed up diagnosis using IFA driving the market growth. Some of the companies which are currently dominating the market are Grifols SA, Abbott Laboratories (Alere Inc.), BioVision Inc., Antibodies Incorporated, and PerkinElmer Inc.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support